These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. Hollifield AL; Arnall JR; Moore DC Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point]. Poullin P Transfus Clin Biol; 2021 Nov; 28(4):380-385. PubMed ID: 34464709 [TBL] [Abstract][Full Text] [Related]
7. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK; N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070 [TBL] [Abstract][Full Text] [Related]
8. Real-world experience with caplacizumab in the management of acute TTP. Dutt T; Shaw RJ; Stubbs M; Yong J; Bailiff B; Cranfield T; Crowley MP; Desborough M; Eyre TA; Gooding R; Grainger J; Hanley J; Haughton J; Hermans J; Hill Q; Humphrey L; Lowe G; Lyall H; Mohsin M; Nicolson PLR; Priddee N; Rampotas A; Rayment R; Rhodes S; Taylor A; Thomas W; Tomkins O; Van Veen JJ; Lane S; Toh CH; Scully M Blood; 2021 Apr; 137(13):1731-1740. PubMed ID: 33150355 [TBL] [Abstract][Full Text] [Related]
9. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab? Picod A; Veyradier A; Coppo P J Thromb Haemost; 2021 Jan; 19(1):58-67. PubMed ID: 33236389 [TBL] [Abstract][Full Text] [Related]
11. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies. Mazepa MA; Park YA; Raval JS Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275 [TBL] [Abstract][Full Text] [Related]
12. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment. Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094 [TBL] [Abstract][Full Text] [Related]
13. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Coppo P; Bubenheim M; Azoulay E; Galicier L; Malot S; Bigé N; Poullin P; Provôt F; Martis N; Presne C; Moranne O; Benainous R; Dossier A; Seguin A; Hié M; Wynckel A; Delmas Y; Augusto JF; Perez P; Rieu V; Barbet C; Lhote F; Ulrich M; Rumpler AC; de Witte S; Krummel T; Veyradier A; Benhamou Y Blood; 2021 Feb; 137(6):733-742. PubMed ID: 33150928 [TBL] [Abstract][Full Text] [Related]
14. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600 [TBL] [Abstract][Full Text] [Related]
15. Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms. Coppo P; Transfus Apher Sci; 2017 Feb; 56(1):52-56. PubMed ID: 28110841 [TBL] [Abstract][Full Text] [Related]